Companion Diagnostic Guides Colorectal Cancer Treatment
By LabMedica International staff writers Posted on 18 Jul 2012 |
Image: Rotor-Gene Q MDx for the therascreen KRAS assay (Photo courtesy of Qiagen).
A companion diagnostic kit guides treatment for metastatic colorectal cancer patients for whom surgery and chemotherapy are insufficient.
The therascreen KRAS RGQ polymerase chain reaction (PCR) kit (therascreen KRAS test) provides guidance on the use of Erbitux (cetuximab, EGFR) as a treatment in patients with metastatic colorectal cancer. This companion diagnostic assay is used to determine the presence of mutations in the human KRAS gene that assist in identifying colorectal cancer patients most likely to benefit from anti-EGFR therapies.
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved the KRAS RGQ PCR Kit for use in the US. The manufacturer of the KRAS test kit, Qiagen (Hilden, Germany), already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.
In contrast to laboratory-developed tests (LDTs), the FDA-approved therascreen KRAS test gives healthcare providers a fast, consistent, and reliable process to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-inhibitor therapy.
The therascreen KRAS test offers laboratories an efficient workflow based on the Rotor-Gene Q MDx, an automated molecular detection instrument that uses real-time PCR technology. All other companion diagnostics in development, as well as a range of other molecular diagnostic tests, are being developed for US regulatory approval on the Rotor-Gene Q MDx.
The therascreen KRAS kit is the second assay cleared/approved by the FDA for use on the Rotor-Gene Q MDx. Earlier in 2012, Qiagen's artus Infl A/B RG RT-PCR for the detection of Influenza A/B was cleared for use on Rotor-Gene Q MDx, with the instrument also receiving FDA 510(k) clearance at the same time.
Related Links:
US Food and Drug Administration
Qiagen
The therascreen KRAS RGQ polymerase chain reaction (PCR) kit (therascreen KRAS test) provides guidance on the use of Erbitux (cetuximab, EGFR) as a treatment in patients with metastatic colorectal cancer. This companion diagnostic assay is used to determine the presence of mutations in the human KRAS gene that assist in identifying colorectal cancer patients most likely to benefit from anti-EGFR therapies.
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved the KRAS RGQ PCR Kit for use in the US. The manufacturer of the KRAS test kit, Qiagen (Hilden, Germany), already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.
In contrast to laboratory-developed tests (LDTs), the FDA-approved therascreen KRAS test gives healthcare providers a fast, consistent, and reliable process to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-inhibitor therapy.
The therascreen KRAS test offers laboratories an efficient workflow based on the Rotor-Gene Q MDx, an automated molecular detection instrument that uses real-time PCR technology. All other companion diagnostics in development, as well as a range of other molecular diagnostic tests, are being developed for US regulatory approval on the Rotor-Gene Q MDx.
The therascreen KRAS kit is the second assay cleared/approved by the FDA for use on the Rotor-Gene Q MDx. Earlier in 2012, Qiagen's artus Infl A/B RG RT-PCR for the detection of Influenza A/B was cleared for use on Rotor-Gene Q MDx, with the instrument also receiving FDA 510(k) clearance at the same time.
Related Links:
US Food and Drug Administration
Qiagen
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing